Who are ASC enriched lipofilling's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cellular Matrix / A-CP-HA Kit, Autologous platelets rich plasma, ACP, Low-dose PRP, Leukocyte rich platelet rich plasma, Platelet Rich Plasma (PRP).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/asc-enriched-lipofilling.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

ASC enriched lipofilling — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ASC enriched lipofilling (ASC enriched lipofilling) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cell therapy / Regenerative medicine. Area: Regenerative Medicine / Plastic and Reconstructive Surgery.

phase 3 Cell therapy / Regenerative medicine Regenerative Medicine / Plastic and Reconstructive Surgery Biologic Live · refreshed every 30 min

Target snapshot

ASC enriched lipofilling (ASC enriched lipofilling) — Stemform. ASC enriched lipofilling uses adipose-derived stem cells (ASCs) combined with autologous fat to promote tissue regeneration and improve graft survival in soft tissue augmentation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
ASC enriched lipofilling TARGET	ASC enriched lipofilling	Stemform	phase 3	Cell therapy / Regenerative medicine
Cellular Matrix / A-CP-HA Kit	Cellular Matrix / A-CP-HA Kit	Fundación Santiago Dexeus Font	marketed	Cell therapy / Regenerative medicine product
Autologous platelets rich plasma	Autologous platelets rich plasma	Mostafa Hassanein, Msc	marketed	Autologous cell therapy / Regenerative medicine product
ACP	ACP	Istituto Ortopedico Rizzoli	marketed	Cell therapy / Regenerative medicine product
Low-dose PRP	Low-dose PRP	Hospital for Special Surgery, New York	marketed	Autologous cell therapy / Regenerative medicine product
Leukocyte rich platelet rich plasma	Leukocyte rich platelet rich plasma	University Hospitals Cleveland Medical Center	marketed	Autologous cell therapy / Regenerative medicine product
Platelet Rich Plasma (PRP)	Platelet Rich Plasma (PRP)	Aspetar	marketed	Autologous cell therapy / Regenerative medicine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cell therapy / Regenerative medicine class)

American University of Beirut Medical Center · 1 drug in this class
Kuhnil Pharmaceutical Co., Ltd. · 1 drug in this class
Stemform · 1 drug in this class
Taejoon Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ASC enriched lipofilling — Competitive Intelligence Brief. https://druglandscape.com/ci/asc-enriched-lipofilling. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing